Canada is known for its large mineral deposits. With the introduction of new technologies, previously thought irrecoverable oil and gas reserves have seen the light of day giving the industry a new push. The province of Alberta especially, has seen the return of old names, and the arrival of new ones.
Two companies that have been around for some time now are Imperial Oil (IMO) and Pembina Pipeline (PBA). Political instability in the Middle East has also given an extra relevance to the reserves found at this region, so let us see what the future holds and what gurus think of them.
Exxon�� Canadian Child
Imperial Oil is the largest integrated oil company in Canada, operates under the Esso banner, and 70% of it is owned by Exxon (XOM). Activities are concentrated around exploration and production of oil and natural gas, refining and marketing of petroleum products, and manufacture and sale of petrochemicals. With approximately 7,500 employees, production throughout 2012 the firm produced around 300,000 BOE per day. More important to shareholders, the firm has a history of greater than average ROIC, but is not foreign to environmental risks.
Top 5 Services Stocks To Own Right Now: India Fund Inc (IFN)
The India Fund, Inc. (the Fund), incorporated on December 27, 1993, is a non-diversified, closed-end management investment company. The Fund�� investment objective is long-term capital appreciation. It invests in Indian equity securities. At least 80% of the Fund�� total assets are invested in equity securities of Indian companies. Its portfolio includes common stocks, warrants and short-term investments. The India Fund, Inc. operates through a branch in the Republic of Mauritius.
The India Fund, Inc. invests in a range of industries, including computer software and programming, computer services, finance, diversified industries, building and construction, cement, chemicals, electronics and electrical equipment, extractive industries, engineering, diversified financial services, petroleum-related industries, pharmaceuticals, steel and telecommunications. Aberdeen Asset Management Asia Limited is the Fund�� investment manager.
Advisors' Opinion:- [By Jon C. Ogg]
WisdomTree�India Earnings Fund (NYSEMKT: EPI) is down yet another 2.7% at $13.05, and it hit a new low of $13.00 on Wednesday against a high of $20.50. The PowerShares India (NYSEMKT: PIN) is down another 2.5% at $13.54, and it hit a new low with its 52-week range now at $13.50 to $19.66. The India Fund Inc. (NYSE: IFN) is a closed-end fund rather than an exchange traded fund (ETF), and it is down almost 1.75% at $16.95, with its shares hitting a new multiyear low of 416.88, against a 52-week high of $24.10.
- [By Jon C. Ogg]
The India Fund Inc. (NYSE: IFN) is a closed-end fund that trades often at severe discounts or premiums to the net asset value. Its gain is only 0.9% to $18.03, and the 52-week trading range of $16.88 to $24.10 implies that it has recovered only 7% off of its recent lows. It currently trades at a discount of 11% to its NAV according to CEFA.com.
- [By Jon C. Ogg]
The India Fund Inc. (NYSE: IFN) is down another 5% at $17.55 against a 52-week range of $17.53 to $24.10. CEFA.com shows that it trades at roughly a 9.4% discount to its net asset value.
Hot Healthcare Equipment Stocks For 2014: Cell Therapeutics Inc (CTIC)
Cell Therapeutics, Inc. (CTI), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company�� research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors. Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. As of December 31, 2011, it also developed tosedostat in collaboration with Chroma Therapeutics, Ltd. (Chroma). On May 31, 2012, CTI completed its acquisition gaining worldwide rights to S*BIO Pte Ltd.'s (S*BIO) pacritinib.
Pixuvri
As of December 31, 2011, the Company developed Pixuvri, an aza-anthracenedione derivative, for the treatment of non-Hodgkin�� lymphoma (NHL), and various other hematologic malignancies, and solid tumors. Pixuvri was studied in the Company�� EXTEND, or PIX301, clinical trial, which was a phase III single-agent trial of Pixuvri for patients with relapsed, refractory aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. On September 28, 2011, CTI announced that a second independent radiology assessment of response and progression endpoint data from its PIX301 clinical trial of Pixuvri was achieved with statistical significance. The results of the EXTEND trial met its primary endpoint and showed that patients randomized to treatment with Pixuvri achieved a significantly higher rate of confirmed and unconfirmed complete response compared to patients treated with standard chem! otherapy had a significantly increased overall response rate and experienced a statistically significant improvement in median progression free survival. Pixuvri had predictable and manageable toxicities when administered at the proposed dose and schedule in the EXTEND clinical trial in heavily pre-treated patients. In March 2011, the Company initiated the PIX-R trial to study Pixuvri in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Pixuvri has also been studied in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. In the second quarter of 2010, the NCCTG opened this phase II study for enrollment. The study is closed to accrual and results are expected to be reported by the NCCTG later in 2012.
OPAXIO
OPAXIO is the Company�� biologically-enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. As of December 31, 2011, the Company focused its development of OPAXIO on ovarian, brain, esophageal, head and neck cancer. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. In November 2010, results were presented by the Brown University Oncology Group from a phase II trial of OPAXIO combined with temozolomide (TMZ), and radiotherapy in patients with newly-diagnosed, high-grade gliomas, a type of brain cancer. The trial demonstrated a high rate of complete and partial responses and a high rate of six month progression free survival (PFS). Based on these results, the Brown University Oncology Group has initiated a randomized, multicenter, phase II study of OPAXIO and standard radiotherapy versus TMZ and radiotherapy for newly diagnosed patients with glioblastoma with an active gene termed MGMT that reduces responsiveness to TMZ. A phase I/II study of OPAXIO combined with radi! otherapy ! and cisplatin was initiated by SUNY Upstate Medical University, in patients with locally advanced head and neck cancer.
Tosedostat
In March 2011, the Company entered into a co-development and license agreement with Chroma Therapeutics, Ltd. (Chroma), providing the Company with marketing and co-development rights to Chroma�� drug candidate, tosedostat, in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood related cancers and solid tumors in phase I-II clinical trials. Interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) showed that once-daily, oral doses of tosedostat had predictable and manageable toxicities and results demonstrated response rates, including a high-response rate among patients who received prior hypomethylating agents, which are used to treat myelodysplastic syndrome (MDS), a precursor of AML.
Brostallicin
As of December 31, 2011, the Company developed brostallicin through its wholly owned subsidiary, Systems Medicine LLC, which holds rights to use, develop, import and export brostallicin. Brostallicin is a synthetic deoxyribonucleic acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity and a favorable safety profile in clinical trials, in which more than 230 patients have been treated as of December 31, 2011. The Company uses a genomic-based platform to guide the development of brostallicin. A phase II study of brostallicin in relapsed, refractory soft tissue sarcoma met its predefined activity and safety hurdles and resulted in a first-line phase II clinical trial study that was conducted by the European Organization for Research and Treatment of Cancer (EORTC).
The Company competes with Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Roche Group, Genentech, Inc., Astellas Pharma, Eli Lilly and Company, Celgene, Telik, I! nc., TEVA! Pharmaceuticals Industries Ltd. and PharmaMar.
Advisors' Opinion:- [By Sean Williams]
Cell Therapeutics (NASDAQ: CTIC )
Certainly no discussion of companies with large accumulated deficits would be complete without discussing a biotechnology company. It's perfectly understandable to see a biotech, especially a clinical-stage one, run with an accumulated deficit, as it takes time and money to build up a drug pipeline. However, after multiple complete response letters (the equivalent of a rejection) by the Food and Drug Administration and years without an approved drug, Cell Therapeutics racked up an astounding $1.83 billion in accumulated deficits through the end of fiscal 2012. By comparison, that's nearly 56 times larger than its shareholder equity.�
Hot Healthcare Equipment Stocks For 2014: Evolva Holding SA (EVE)
Evolva Holding SA (Evolva) discovers and provides ingredients for health, nutrition and wellness. Evolva uses biosynthetic and evolutionary technologies to create small molecule compounds and their production routes. The Company�� nutrition and consumer products include Pomecins, saffron, stevia, vanilla and resveratrol. The Company�� pharmaceuticals products include EV-077 and EV-035. In pharmaceuticals, the Company focuses on oral, small molecule drugs with application in complications of diabetes and infectious diseases. Pomecins are Evolva�� compounds. Evolva is focused on two members of the family - Pomecin A and Pomecin B. EV-035 is a bacterial type II topoisomerase inhibitor. Evolva is developing EV-077 for the treatment of diabetic complications. It is an oral, small molecule compound, belonging to a structural class. Advisors' Opinion:- [By Glenwoods]
Earlier this year the giant food processor, Cargill, partnered with the small Swiss company, Evolva (SIX:EVE), which was developing its own stevia-based fermentation process, also in the pilot stage. As noted earlier in the article, Cargill is in a partnership with Coca-Cola for Truvia, the bestselling stevia product on the market. The success of the Cargill/Evolva partnership could have big implications not just for Cargill and Coca-Cola, but also on the entire stevia and sweetener market. I further believe the success of the partnership could have a major impact on Stevia First. If Cargill�� fermentation method produces a better tasting stevia product at a lower cost it would give Coca-Cola a considerable advantage over the other beverage bottlers, food manufacturers, and stevia producers. Such an outcome would force these companies to scramble to find a similar method in order to compete. There would be a very good chance that rival companies, in order to stay in the game, would have to turn to the other company developing a fermentation-based stevia product-- Stevia First. If that happens Stevia First�� value would rise considerably.
Hot Healthcare Equipment Stocks For 2014: PMC - Sierra Inc.(PMCS)
PMC-Sierra, Inc. engages in the design, development, marketing, and support of semiconductor solutions for the enterprise infrastructure and communications infrastructure markets. Its products include controllers based on Fibre Channel, Serial Attached SCSI, and Serial ATA that enable the development of external and server-attached storage systems; framers and mappers, which convert the data into a format for transmission in the network before the data is sent to the next destination; line interface units that transmit and receive signals over a physical medium, such as wire, cable, or fiber; and microprocessor-based system-on-chips, which perform the high-speed computations that help in identifying and controlling the flow of signals and data in various network equipment used in the communications, storage, and enterprise markets. The company also offers packet and cell processors that examine the contents of cells or packets, and perform various management and reporting functions; radio frequency transceivers, which transmit and receive broadband signals over the air; and serializers/deserializers that convert and multiplex traffic between slower speed parallel streams and higher speed serial streams. PMC-Sierra sells its products to end customers directly, as well as through distributors and independent manufacturers? representatives primarily in China, Asia, Japan, Taiwan, Europe, the United States, and the Middle East. The company was founded in 1983 and is based in Santa Clara, California.
Advisors' Opinion:- [By CRWE]
PMC (Nasdaq:PMCS), the semiconductor innovator transforming networks that connect, move and store big data, reported that the Company will present at the Citi 2012 Technology Conference on September 5, 2012, in New York, NY.
Hot Healthcare Equipment Stocks For 2014: PDF Solutions Inc.(PDFS)
PDF Solutions, Inc. provides infrastructure technologies and services for the design and manufacture of integrated circuits (IC) in Asia, the United States, and Europe. It offers manufacturing process solutions that include process research and development, and process integration and yield ramp; volume manufacturing solutions; and design-for-manufacturability (DFM) solutions, such as logic DFM, circuit level DFM, memory DFM, and pdBRIX Physical IP solutions. The company also offers characterization vehicle (CV) infrastructure, which includes CV test chips, pdCV analysis software, and pdFasTest electrical wafer test system; Yield Ramp Simulator software that analyzes an IC design to compute its systematic and random yield loss; and Circuit Surfer software, which estimates the parametric performance yield and manufacturability of analog/mixed-signal/RF blocks. In addition, it provides pdBRIX platform, which includes software for identifying and developing a set of physical IP building blocks that are tailored to a given manufacturing process and target product application; dataPOWER YMS platform that collects yield data, loads, and stores it in an integrated database and allows product engineers to identify and analyze production yield issues; FDC software, which provides fault detection and classification capabilities to identify sources of process variations and manufacturing excursions by monitoring equipment parameters; and YA-FDC service and software platform that allows online modeling to create real-time virtual measurements of final product attributes during processing. PDF Solutions sells its technologies and services through direct sales force, sales representatives, and strategic alliances to integrated device manufacturers, fabless semiconductor design companies, and foundries in the microprocessors, memory, graphics, image sensor solutions, and communications segments. The company was founded in 1992 and is headquartered in San Jo se, California.
Advisors' Opinion:- [By Roberto Pedone]
PDF Solutions (PDFS) provides infrastructure technologies and services to improve yield and optimize performance of integrated circuits. This stock closed up 2.6% at $21.51 in Friday's trading session.
Friday's Volume: 543,000
Three-Month Average Volume: 112,159
Volume % Change: 393%From a technical perspective, PDFS trended up here right above some near-term support at $20.50 and into new 52-week-high territory with above-average volume. This stock has been uptrending strong for the last three months, with shares moving higher from its low of $14.95 to its intraday high on Friday of $21.64. During that move, shares of PDFS have been consistently making mostly higher lows and higher highs, which is bullish technical price action. That move has also been accompanies by heavy upside volume flows since mid-July.
Traders should now look for long-biased trades in PDFS as long as it's trending above some near-term support at $20.50 or above its 50-day at $19.06 and then once it sustains a move or close above Friday's high of $21.64 with volume that's near or above 112,159 shares. If we get that move soon, then PDFS will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $25 to $28.
- [By Magic Diligence]
Liberator is a direct-to-consumer provider of medical supplies, primarily urological catheters, ostomysupplies, mastectomy fashions, and diabetic supplies, aimed at Medicare-eligible seniors. The company has an attractive revenue growth ramp, with sales growing at a 5-year average of nearly 50%. This has leveraged costs, leading margins up from just 5% in 2011 to 18% today. Liberator pays a 4.3% dividend yield and has a solid balance sheet with $20 million in cash and just $3 million in debt. Below $3, the stock is at the bottom of its 52-week range.
PDF Solutions Inc (PDFS)Far from an electronic document company, PDF Solutions provides software, IP, hardware, and services designed to speed the process and lower the cost of designing and manufacturing custom integrated circuits (ICs), especially in the area of yield improvements. PDFS has booked solid 3-year average revenue growth of 18%, has exploded operating margins from 2% in 2010 to over 35% today, generates free cash flow in excess of net income, and has no debt with a nice cash cushion of $65 million. At under $13, the stock is more than 50% below its 52-week high and carries a bargain 12% earnings yield.
- [By Lisa Levin]
PDF Solutions (NASDAQ: PDFS) shares reached a new 52-week low of $12.91. PDF Solutions updated the status of certain contracts and announced the effect of the change in status on previously deferred costs and expected revenues.
Hot Healthcare Equipment Stocks For 2014: Dover Motorsports Inc (DVD)
Dover Motorsports, Inc. is a marketer and promoter of motorsports entertainment in the United States. The Company, through its subsidiaries, owned and operated Dover International Speedway in Dover, Delaware and Nashville Superspeedway near Nashville, Tennessee. During the year ended 2011, the Company�� facilities promoted 10 events under the auspices of the sanctioning body, the National Association for Stock Car Auto Racing (NASCAR). During 2011, the Company promoted 2 NASCAR Sprint Cup Series events, 4 NASCAR Nationwide Series events, 3 NASCAR Camping World Truck Series events, and 1 NASCAR K&N Pro Series East event.. On January 31, 2011, the Company sold its Memphis Motorsports Park facility.
Dover International Speedway
The Company has promoted NASCAR-sanctioned racing events at Dover International Speedway. As of December 31, 2011, it promoted six NASCAR-sanctioned events at the facility annually. Two races are in the NASCAR Sprint Cup Series professional stock car racing circuit, two races are in the NASCAR Nationwide Series racing circuit, one race is in the NASCAR Camping World Truck Series racing circuit and one race is in the NASCAR K&N Pro Series East racing circuit. Each of the NASCAR Nationwide Series events and the Camping World Truck Series event at Dover International Speedway are conducted on the days before a NASCAR Sprint Cup Series event. Dover International Speedway is one of only seven speedways in North America that presents two NASCAR Sprint Cup Series events and two NASCAR Nationwide Series events each year. Additionally, it is one of only five tracks to host three NASCAR events at one facility on the same weekend.
Dover International Speedway, known as the Monster Mile, is a high-banked, one-mile, concrete superspeedway with permanent seating capacity of approximately 132,000. The superspeedway facility also features the Monster Bridge. The climate controlled bridge spans across the width of the superspeedway at a height of 29 feet ! and houses 50-luxury seats, a refreshment bar and other amenities.
Nashville Superspeedway
Nashville Superspeedway (Nashville) is a motorsports complex approximately 35 miles from downtown Nashville in Wilson County, Tennessee. The 1.33-mile concrete superspeedway has 25,000 permanent grandstand seats with an infrastructure in place to expand to 150,000 seats as demand requires. Additionally, construction included lights at the superspeedway to allow for nighttime racing and the foundation work for a dirt track, short track and drag strip. Nashville Superspeedway promoted two NASCAR Nationwide Series events and two NASCAR Camping World Truck Series event, during 2011. The facility also hosted other regional and national touring events, as well as track rentals.
Advisors' Opinion:- [By CRWE]
Dover Motorsports, Inc. (NYSE:DVD) Board of Directors today declared an annual cash dividend on both classes of common stock of $.04 per share. The dividend will be payable on December 10, 2012 to shareholders of record at the close of business on November 10, 2012. Due to the seasonal nature of our business, we will evaluate dividends annually.
No comments:
Post a Comment